Fractyl Health (GUTS) Q2 2024 earnings summary

Executive summary

• Achieved FDA Breakthrough Device Designation for Revita in weight maintenance after GLP-1 drug discontinuation, with pivotal studies ongoing in the US and Europe and protocol expansion increasing eligible US patients nearly six-fold.

• Real-world registry in Germany demonstrated median 13% weight loss and HbA1c reduction from 9.6% to 7.2% at 12 months in hard-to-treat patients with obesity and type 2 diabetes.

• Rejuva gene therapy platform showed robust preclinical results, including superior and durable weight loss versus semaglutide, reduced liver fat and cholesterol, and plans for candidate nomination in H2 2024.

• Completed IPO in February 2024, raising $98.9 million net, with all preferred stock and convertible notes converted to common stock.

• Leadership transition with Ajay Royan appointed as new chair of the board, succeeding Allan Will in August 2024.

Financial highlights

• Q2 2024 net loss was $17.2 million, improved from $30.2 million in Q2 2023, mainly due to non-cash changes in fair value of notes and increased interest income.

• R&D expenses rose to $16.8 million in Q2 2024 from $9.1 million in Q2 2023, driven by clinical study initiations and personnel costs.

• SG&A expenses increased to $6.2 million from $2.8 million year-over-year, mainly due to public company costs and personnel expenses.

• Cash and cash equivalents stood at $102.4 million as of June 30, 2024, up from $33.2 million at year-end 2023, expected to fund operations through Q4 2025.

• Revenue for Q2 2024 was $43,000, all from a pilot commercial launch in Germany.

Outlook and guidance

• Cash runway projected through Q4 2025 based on current development plans.

• Initial data from REVEAL-1 open-label cohort for weight maintenance expected in Q4 2024; mid-point data from REMAIN-1 pivotal study in Q2 2025.

• Top-line data from the expanded Revitalize-1 pivotal study for type 2 diabetes expected in mid-2025.

• IND-enabling studies for Rejuva-1 gene therapy candidate to be completed in H2 2024, with first-in-human studies targeted for H1 2025.

• Continued increases in R&D and SG&A expenses anticipated as clinical programs and commercialization efforts expand.